Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
French Innovative Leukemia Organisation
With
Hoffmann-La Roche
All patients at diagnosis with a stage II, III or IV an arbor disease are treated with 4 cycles of (R VAD +C) .
The responders more than RP \> 50% received 2 other cycles before to be intensified with alkeran 140 mg/ m2 and a 8 grays TBI over 4 days before an autologous PBSCT.The stem cell collection is realised after a mobilisation with HD Cyclophosphamide (4 mg/m2) after the four R-(VAD + C) cycles and purged by a rituximab injection 10 days before the collection.
There is an clinical and molecular evaluation of the strategy
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mantel cell lymphoma
CD 20+
At diagnosis or without anterior chemotherapy
Age \>18 and \< 66 years
Ann Arbor ii, III or IV
ECOG \<3
contraindication for rituximab treatment
Informed consent signed
No cancer anteriory
Renal and hepatic function compatible with the treatment
Ventricular Fraction \> 50 % with echographic method and \> 40% with isotopic method